

Capricorn Company Presentation

2020

V1

- **Business Units & Projects**
 - **Consulting and Interim Management**
 - **Clients and Projects**
 - **Vaccine Development for Humans and Animals**
- **Family of obtained Influenza NS Vectors**
- **Platform Technology**
- **Team**

+ Consulting

- Business Development, Commercial Operations, among others for www.gpnvaccines.com (universal strep. pneumoniae vaccine)
- Small Molecules, Development and Manufacturing
- GMP Manufacturing of a Universal Influenza Vaccine candidate

+ Interim Management

- Business Development, M&S, General Management
- Placement of interim managers for all functions

+ Vaccine Development Programs

- Human Vaccines: Universal Influenza, SARS-CoV-2
- Human Oncolytic Virus
- Animal Vaccines: Universal Influenza, Porcine Circovirus 2

+ Biochemical Analysis for Small Molecules



*selection

Area	Project
Business Development	Search for strategic partners
	International market entrance studies
	Market assessment, national or global
M&S	Compilation of marketing & sales plans
	Implementation of sales structures
	Generation of sales
General Management	Management of biotech companies
	Set up of laboratories incl. BSL and GMO certifications
Human Resources	Placement of (interim) managers, e.g. finance, HR, manufacturing, QA, QC, supply chain management

*selection

Vaccines and Oncolytic Virus for Humans


Type	Disease	Stage	Status
Vaccine	Influenza, universal	Pre-clinical, mice and piglets	To get funded or partnered
Vaccine	Influenza, universal	Phase I, patenting ongoing	Client vaccine. To get funded or partnered
Vaccine	SARS-CoV-2	Development, GMO designed	To get funded, partnered or divested
Vaccine	SARS-CoV-2	Development, vaccine candidates obtained	Client vaccine. To get funded or partnered
Vaccine	RSV	Not yet initiated	Not yet initiated
Vaccine	Tuberculosis	Not yet initiated	Not yet initiated
Oncolytic Virus, vector dependent on Neutrophilic Elastase (NE)	Solid tumors (not lung)	Development, virus designed	To get funded or partnered

Vaccines for Animals

Animal	Disease	Stage	Status
1. Swine (piglets)	Influenza, universal	Tested in mice and piglets.	Final pivotal trial pending. To get funded or partnered.
2. Swine (piglets)	Porcine Circovirus 2 (based on universal influenza vaccine)	Vaccine candidates obtained	To get funded or partnered.

Family of obtained influenza NS vectors

Vectors created by Prof. Egorov:



HIV: Nef	Pre-clinical
Mycobacteria tuberculosis	Phase 1 completed
Human IL-2	Pre-clinical
Influenza conserved epitopes	Phase 1 completed
SARS-CoV-2 (COVID-19)	Pending
Brucella Abortus	Licensed in Kazakhstan
Influenza, universal, for pigs	Tested in mice and piglets
Influenza, universal, plus PCV2 for pigs	Pre-clinical

- Genetically stable in 10 days old embryonated eggs
- Applicable for egg or tissue culture manufacturing
- Replication deficient in people
- Induce T-cell immune response to transgene

Influenza NS vectors for intranasal delivery




Simplest route of vaccination

Induction of respiratory associated and systemic CD8+ and CD4+ memory immune response



- Cell Mediated Immunity (CMI) of mucosal surfaces against various pathogens depending on inserted transgene
- CMI against influenza
- Trained Innate Immunity effect leading to temporary protection against unrelated pathogens

The Platform: Construction of influenza vaccine vectors




Martin Götting, CEO

- + > 30 years of experience in big pharma (Hoechst/Behring, Chiron) and small biotech (Intercell AG, AVIR Green Hills Biotechnology)
- + Roles of increasing responsibility in Commercial Operations, Business Development, Supply Chain Management and General Management
- + Since 10+ years working as CEO, interim manager and consultant



Prof. Andrej Egorov, CSO

- + MD, PhD, Professor
- + Virologist, > 30 years experience in influenza research and vaccinology
- + Expert respiratory diseases
- + Advisor at the Institute of Influenza, St. Petersburg, Russia



Dr. Artem Krokhin

- + Senior Scientist at Capricorn
- + Chemist, 8 years of experience in technological development of
- + Various influenza-based vaccines.
- + PhD in Chemistry from the University of Vienna.





Martin Götting
+43 676 930 3370

martin.goetting@capricorn-consilium.com

Prof. Andrej Egorov, MD

+43 676 721 9738

andrej.egorov@capricorn-consulting.com

Office: AT-2440 Reisenberg, An der Wehr 6 – Lab: AT-3430 Tulln, Technopark 1, Building C

www.capricorn-consilium.com